Biotech stocks are languishing close to their early 2020 bottom that they’d dropped to immediately after the onset of the Covid-19 pandemic. The sector was… Read More »7 Biotech Stocks With Key Catalysts For May
“It was a difficult first half for biotech stocks, once again underscoring how conditions may seem so ideal but investment returns can still be hard to generate.”
“Wall Street analysts following these biotechs have high expectations for the drugs they’re developing and in one case already marketing.
If you feel like biotech stocks tend to go down right after you buy them, you’re not alone – and today’s article provides some important insights into what’s going on.
Information collected through genetic testing business has the potential to become a powerful drug developer.
“New therapies derived from psychedelic compounds…are offering hope, not to mention a slew of opportunities for forward-thinking investors.”
Tech companies involved in software, AI and e-commerce, and a medical device company that designs innovative injection technologies, are among the new stocks to watch.
With A Potential Blockbuster Drug, And Ripe For Acquisition, This Biotech Stock Could Be A Big Winner
With a potential $5+ billion drug that could ultimately be used against dozens of diseases, the clinical-stage biotech company discussed in today’s article “is a ripe acquisition target, and when that acquisition comes, it will go for a steep price.”